Takeda: Depressive Disorder, Major trials

The registry lists 26 Depressive Disorder, Major studies with Takeda as lead sponsor. 1 are open to participants now and 24 have results posted.

Phase 2 5Phase 3 17Phase 4 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive DisorderRecruitingNCT07204314Phase 3
• A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With DepressionCompletedNCT05932407Results posted
• Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable TechnologyCompletedNCT03067506Results posted
• Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive DisorderCompletedNCT02972632Phase 4Results posted
• The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using ActigraphyCompletedNCT02669082Phase 4Results posted
• A Phase 3 Study of Lu AA21004 in Patients With Major Depressive DisorderCompletedNCT02389816Phase 3Results posted
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)CompletedNCT02371980Phase 4Results posted
• Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive DisorderCompletedNCT01564862Phase 2Results posted
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyTerminatedNCT01436175Phase 3Results posted
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderCompletedNCT01436162Phase 3Results posted
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderCompletedNCT01436149Phase 3Results posted
• SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderCompletedNCT01435759Phase 2Results posted
• Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual DysfunctionCompletedNCT01364649Phase 3Results posted
• Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive DisorderCompletedNCT01355081Phase 3Results posted
• Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive DisorderCompletedNCT01255787Phase 2/3Results posted
• Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT01179516Phase 3Results posted
• Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT01163266Phase 3Results posted
• Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT01153009Phase 3Results posted
• Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension StudyCompletedNCT01152996Phase 3Results posted
• SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive DisorderCompletedNCT00985725Phase 2Results posted
• Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an AntidepressantCompletedNCT00905424Phase 2Results posted
• Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT00735709Phase 3Results posted
• Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT00707980Phase 3Results posted
• Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive DisorderCompletedNCT00672958Phase 3Results posted
• Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive DisorderCompletedNCT00672620Phase 3Results posted
• Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive DisorderCompletedNCT01395147Phase 3